Company Overview
About Asimov
Asimov is a Boston-based biotechnology and computational biology company founded in 2017 by Alec Nielsen, Raja Srinivas, and Christopher Voigt. The company's mission is to apply software engineering principles to cell engineering — treating genetic circuits in mammalian cells the way software engineers treat code. Asimov builds computational tools and AI models that predict how genetic constructs will behave in mammalian cells, enabling researchers to design, simulate, and optimize biologics and gene therapy vectors before conducting expensive wet lab experiments.
Business Model & Competitive Advantage
The company raised a $75M Series B led by Andreessen Horowitz Bio + Health, with additional participation from DCVC Bio, Lux Capital, and others. Asimov's core platform integrates large-scale experimental data generation (using high-throughput DNA synthesis and cell-based assays) with machine learning models that learn the rules governing gene expression, promoter activity, and regulatory element behavior in specific cell types. This creates a virtuous cycle: data informs models, models predict better constructs, experiments validate and refine the models.
Competitive Landscape 2025–2026
Asimov's primary customers are biopharmaceutical companies and CDMOs (contract development and manufacturing organizations) working on recombinant protein biologics and gene therapies. In biologics manufacturing, optimizing expression cassettes in CHO cells (the workhorse of biologic production) is a critical bottleneck — Asimov's tools can accelerate this process from months to weeks. In gene therapy, designing AAV capsids and expression cassettes that achieve therapeutic levels of protein in target tissues is a major technical challenge that Asimov's computational platform directly addresses.
Key Differentiators
Emerging Innovator
Asimov is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Asimov with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Asimov? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Asimov Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Asimov vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →